Fludarabine triphosphate (trisodium)

Fludarabine triphosphate (trisodium)

• UNSPSC Description: Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC50 of 2.3 μM and a Ki of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis[1][2].
• Target Antigen: Apoptosis; DNA/RNA Synthesis; Drug Metabolite; Nucleoside Antimetabolite/Analog
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/fludarabine-triphosphate-trisodium.html
• Smiles: O[C@@H]([C@@H]1O)[C@](O[C@@H]1CO[P](O[P](O[P](O)(O[Na])=O)(O[Na])=O)(O[Na])=O)([H])N2C3=NC(F)=NC(N)=C3N=C2
• Molecular Weight: 591.12
• References & Citations: [1]Catapano CV, et al. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991 Apr 1;51(7):1829-35. |[2]Woodahl EL, et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol. 2009 Feb;63(3):391-401.
• Shipping Conditions: Blue Ice